(A) Cell-cycle analysis of U251MG GBM cells at 16 hr after treatment with 6 Gy of IR, 100 µM of TMZ, and 1 µM of PD0166285.
(B) Cell-cycle analysis of human primary fibroblasts at 16 hr after treatment.
(C) Quantitation of PHH3 expression in U251MG cells treated with WEE1 siRNA, WEE1 inhibitor, or nontreated.
(D) Western blot analysis of CDC2, phosphorylated CDC2, and β-actin in U251MG GBM cells at 16 hr after treatment.
(E) Representative cell counts of U251MG GBM cells at 4 days after treatment.
(F) WST-1 viability analysis of U251MG cells at 4 days after treatment.
(G) Colony formation of U87MG, U251MG, U118MG, and U373MG, at 7–14 days after treatment.
(H) WST-1 viability analysis of CD133 sorted primary GBM cells at 4 days after treatment. Shown are averages of experiments carried out in triplicate, error bars indicate standard deviation. ***p < 0.001, t test.
See also Figure S3.